{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Pishas KI"],"funding":["Cancer Council Victoria","Victorian Cancer Agency","US National Cancer Institute U54","NHMRC","National Health and Medical Research Council","Therapeutic Innovation Australia Pipeline Accelerator Grant","NHMRC CJ Martin Overseas Biomedical Fellowship","Cancer Systems Biology Center U54 grant"],"pagination":["5644"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8616176"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(22)"],"pubmed_abstract":["Despite high response rates to initial chemotherapy, the majority of women diagnosed with High-Grade Serous Ovarian Cancer (HGSOC) ultimately develop drug resistance within 1-2 years of treatment. We previously identified the most common mechanism of acquired resistance in HGSOC to date, transcriptional fusions involving the ATP-binding cassette (ABC) transporter <i>ABCB1</i>, which has well established roles in multidrug resistance. However, the underlying biology of fusion-positive cells, as well as how clonal interactions between fusion-negative and positive populations influences proliferative fitness and therapeutic response remains unknown. Using a panel of fusion-negative and positive HGSOC single-cell clones, we demonstrate that in addition to mediating drug resistance, <i>ABCB1</i"],"journal":["Cancers"],"pubmed_title":["Phenotypic Consequences of <i>SLC25A40-ABCB1</i> Fusions beyond Drug Resistance in High-Grade Serous Ovarian Cancer."],"pmcid":["PMC8616176"],"funding_grant_id":["APP1111032","APP1161198","ECSG15012","APP1184894","APP1124309","-","U54CA209978"],"pubmed_authors":["Simpson KJ","Cheasley D","Cowley KJ","Vary R","Shembrey CE","Griffiths JI","Bowtell DDL","Pishas KI","Campbell I","Hoang T","Luu J","Smith LK","Christie EL","Rashoo N","White MO","Bild A","Pandey A","Beach JA"],"additional_accession":[]},"is_claimable":false,"name":"Phenotypic Consequences of <i>SLC25A40-ABCB1</i> Fusions beyond Drug Resistance in High-Grade Serous Ovarian Cancer.","description":"Despite high response rates to initial chemotherapy, the majority of women diagnosed with High-Grade Serous Ovarian Cancer (HGSOC) ultimately develop drug resistance within 1-2 years of treatment. We previously identified the most common mechanism of acquired resistance in HGSOC to date, transcriptional fusions involving the ATP-binding cassette (ABC) transporter <i>ABCB1</i>, which has well established roles in multidrug resistance. However, the underlying biology of fusion-positive cells, as well as how clonal interactions between fusion-negative and positive populations influences proliferative fitness and therapeutic response remains unknown. Using a panel of fusion-negative and positive HGSOC single-cell clones, we demonstrate that in addition to mediating drug resistance, <i>ABCB1</i","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Nov","modification":"2026-06-21T03:10:51.657Z","creation":"2022-02-11T13:16:17.151Z"},"accession":"S-EPMC8616176","cross_references":{"pubmed":["34830797"],"doi":["10.3390/cancers13225644"]}}